- Conditions
- Leukemia, Acute Myeloid, Myelodysplastic Syndromes, Classical Hodgkin Lymphoma, Leukemia, B-cell, Leukemia, Hairy Cell, Mastocytosis, Aggressive Systemic, Blastic Plasmacytoid Dendritic Cell Neoplasm, Chronic Myeloid Leukemia
- Interventions
- MGD024
- Drug
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Denver, Colorado • Baltimore, Maryland • Boston, Massachusetts + 4 more
Location Directory
Clinical trials in Denver, Colorado
This page shows live ClinicalTrials.gov search results for Denver, Colorado, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
7463
Shown on this page
12
Current sort
Recently updated
Location scope
Denver, CO
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 1033–1044 of 7,463 matching trials in Denver, CO.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Gastro-enteropancreatic Neuroendocrine Tumor
- Interventions
- CAM2029, Octreotide LAR, Lanreotide ATG
- Drug
- Lead sponsor
- Camurus AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Santa Monica, California • Denver, Colorado + 12 more
- Conditions
- Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1, FSHD2, Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Facioscapulohumeral Muscular Dystrophy 1, Facioscapulohumeral Dystrophy, Facio-Scapulo-Humeral Dystrophy, Facioscapulohumeral Muscular Dystrophy 2, Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1), FSH Muscular Dystrophy, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Landouzy-Dejerine Syndrome
- Interventions
- AOC-1020, Placebo
- Drug
- Lead sponsor
- Avidity Biosciences, Inc.
- Industry
- Eligibility
- 16 Years to 70 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 14
- States / cities
- Orange, California • Palo Alto, California • Denver, Colorado + 11 more
- Conditions
- Multiple Sclerosis
- Interventions
- Ocrelizumab, Antihistamine, Methylprednisolone
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 769 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 24
- States / cities
- Homewood, Alabama • Phoenix, Arizona • Irvine, California + 21 more
- Conditions
- Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Conventional Surgery, Cyclophosphamide, Dactinomycin, Doxorubicin Hydrochloride, Etoposide, Vincristine Sulfate Liposome
- Radiation · Procedure · Drug + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 29 Years
- Enrollment
- 395 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2026
- U.S. locations
- 199
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 143 more
- Conditions
- Heart Failure NYHA Class III
- Interventions
- Cordella™ Pulmonary Artery Sensor System
- Device
- Lead sponsor
- Endotronix, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 738 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 70
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 57 more
- Conditions
- Renal Transplantation
- Interventions
- Alemtuzumab, rabbit antithymocyte globulin, Belatacept, Tacrolimus, Mycophenolate mofetil, early cessation of steroids
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 316 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 8
- States / cities
- San Francisco, California • Denver, Colorado • Tampa, Florida + 4 more
- Conditions
- Anorexia in Adolescence, Anorexia Nervosa, Anorexia Nervosa, Atypical, Anorexia Nervosa, Binge Eating/Purging Type, Anorexia Nervosa Restricting Type, Anorexia Nervosa With Significantly Low Body Weight, Body Composition Changes, Growth & Development, Malnutrition Severe, Malnutrition, Calorie
- Interventions
- Not listed
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 15 Years to 26 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2031
- U.S. locations
- 2
- States / cities
- San Francisco, California • Denver, Colorado
- Conditions
- Excessive Sleepiness, Shift-work Disorder
- Interventions
- Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 44
- States / cities
- Auburn, Alabama • Cullman, Alabama • Chandler, Arizona + 37 more
- Conditions
- Kidney Diseases, Chronic Kidney Diseases
- Interventions
- Community health worker intervention, Standard Care (in control arm)
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 448 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Denver, Colorado • Albuquerque, New Mexico
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- sigvotatug vedotin, docetaxel
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 762 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 130
- States / cities
- Anchorage, Alaska • Fullerton, California • Los Alamitos, California + 91 more
- Conditions
- HER2-positive Breast Cancer
- Interventions
- tucatinib, placebo, T-DM1
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 466 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 321
- States / cities
- Mobile, Alabama • Gilbert, Arizona • Goodyear, Arizona + 180 more